The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | What’s new in essential thrombocythemia in 2025?
In this video, Alexander Coltoff, MD, Medical University of South Carolina, Charleston, SC, briefly outlines the key points of his talk on updates in essential thrombocythemia (ET). Dr Coltoff notes that the area of second-line treatment is rapidly evolving, with novel agents being investigated. He mentions the topline results of the SURPASS ET trial (NCT04285086), which have shown significant benefits of ropeginterferon alfa-2b over anagrelide in controlling blood counts, reducing thrombohemorrhagic events, and decreasing driver allele burden in this patient population. Additionally, he emphasizes the potential of therapies targeting mutant calreticulin (CALR), which may offer a more targeted and individualized approach for treating ET. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
I think 2025 is a very interesting time for ET treatment and for patients and providers. My talk really focused on two main aspects of treatment. One, the second-line patient who’s seen hydroxyurea and either has some side effects or doesn’t have therapeutic benefit with it. There has been recent publication or top-line results of the SURPASS-ET trial, which studied ropeginterferon versus anagrelide for the second-line treatment of patients with ET, and that found significant benefit for ropeginterferon versus anagrelide, not only in blood count control, but decreases in thrombohemorrhagic events, as well as decreases in the driver allele burden, which we believe might be linked to disease progression...
I think 2025 is a very interesting time for ET treatment and for patients and providers. My talk really focused on two main aspects of treatment. One, the second-line patient who’s seen hydroxyurea and either has some side effects or doesn’t have therapeutic benefit with it. There has been recent publication or top-line results of the SURPASS-ET trial, which studied ropeginterferon versus anagrelide for the second-line treatment of patients with ET, and that found significant benefit for ropeginterferon versus anagrelide, not only in blood count control, but decreases in thrombohemorrhagic events, as well as decreases in the driver allele burden, which we believe might be linked to disease progression. On top of that, there’s studies looking at LSD1 inhibitors like bomedemstat, as well as other agents in the second-line setting. So I think that’s one very rapidly evolving area.
And the other thing I focused on really was the development of these CALR-specific therapies, which could be treatment options for up to a third of patients with ET and are a more targeted and individualized approach for treating this disease than the kind of blanket approach of hydroxyurea or interferon for everyone.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Speaking fees: Incyte, Blueprint Medicines, Sobi; Advisory Boards: PharmaEssentia, Blueprint Medicines.
